Lactylation-Driven NSUN2 m5C RNA Modification Fuels Nerve Invasion in PDAC

Study Background and Research Question

Perineural invasion (PNI) is a defining and clinically challenging feature of pancreatic ductal adenocarcinoma (PDAC), strongly associated with early dissemination, relapse, and poor prognosis. Approximately 80–100% of PDAC cases display PNI, and its presence is a negative prognostic marker regardless of tumor stage (reference). Despite its clinical significance, the molecular drivers linking tumor metabolism to perineural invasion remain incompletely understood. Recent attention has focused on post-translational modifications, such as lysine lactylation, as potential mediators of cancer progression under metabolic stress. The RNA methyltransferase NSUN2, known for catalyzing 5-methylcytosine (m5C) modification on RNA, has been implicated in modulating cancer cell invasion and metastasis, but its specific role in lactate-driven PNI has not previously been defined. This study addresses the central question: How does lactate-induced post-translational modification of NSUN2 influence neural invasion in pancreatic cancer?

Key Innovation from the Reference Study

The primary innovation lies in the discovery that lysine lactylation of NSUN2 at residue K692, driven by elevated lactate in the tumor microenvironment, enhances NSUN2 stability and function. This lactylated NSUN2 catalyzes m5C modification on transcripts such as CDCP1 and STC1, ultimately stabilizing these mRNAs and promoting their pro-invasive functions. This mechanistic axis, termed the lactate–NSUN2–m5C–CDCP1/STC1 pathway, directly connects metabolic stress to the molecular machinery underpinning perineural invasion (reference). The study highlights lactylation as both a regulatory switch and a therapeutic target for restraining neural invasion in PDAC.

Methods and Experimental Design Insights

To elucidate this pathway, the authors employed a multifaceted approach:

• Clinical association studies: Tumor samples from human PDAC cohorts were analyzed for pan-lactylation, NSUN2 lactylation, and PNI severity, with survival follow-up data establishing clinical relevance.
• Cellular functional assays: PDAC cell lines were subjected to migration and invasion assays, as well as dorsal-root-ganglion (DRG) co-culture and neurite-outgrowth assays, under varying lactate conditions and with enzymatic perturbations to modulate lactylation.
• Mechanistic interrogation: NSUN2 knockout and CRISPR knock-in mutants (K692R/E) were generated to test the effects of site-specific lactylation. Co-immunoprecipitation, RNA immunoprecipitation sequencing (RIP-seq), methylated RNA immunoprecipitation qPCR (MeRIP-qPCR), and actinomycin-D chase assays were used to define NSUN2’s RNA targets, assess m5C modification, and measure mRNA stability.
• In vivo validation: A murine sciatic nerve invasion model and a KPC genetically engineered mouse model were used to assess tumor–nerve infiltration and disease progression in response to altered NSUN2 lactylation.

The integration of patient-derived data, cell-based functional assays, and in vivo animal models provides a comprehensive evaluation of the pathway’s biological and clinical significance.

Core Findings and Why They Matter

The study's key results include:

• Upregulation of lactylated NSUN2 in PNI: Both human and mouse PDAC tissues with severe perineural invasion show marked increases in NSUN2 lactylation, which correlates with reduced patient survival (reference).
• Lactate accumulation enhances NSUN2 function: Elevated lactate leads to NSUN2 lactylation at K692, which inhibits NSUN2 ubiquitination and subsequent degradation, increasing its protein abundance.
• NSUN2–m5C modification stabilizes pro-invasive RNAs: Lactylated NSUN2 preferentially binds and methylates CDCP1 and STC1 mRNAs, increasing their half-life and expression. Both genes are implicated in cell motility and invasion.
• Functional impact on tumor–nerve interactions: Inhibition of NSUN2 or lactylation, as well as introduction of K692R/E NSUN2 mutants, reduces PDAC cell invasion in vitro and tumor–nerve infiltration in vivo, confirming the pathway’s centrality to PNI.

These findings establish a direct molecular bridge between metabolic adaptation and the epitranscriptomic regulation of pro-metastatic gene expression, providing actionable targets for therapeutic intervention in aggressive pancreatic cancer.

Comparison with Existing Internal Articles

While this reference study focuses on the mechanisms of neural invasion in pancreatic cancer, internal resources such as "Puromycin Aminonucleoside: Insights into Podocyte Morphol..." and "Puromycin aminonucleoside: Reliable Podocyte Injury Model..." provide detailed guidance on using the aminonucleoside moiety of puromycin in nephrology research. These articles reinforce the value of model systems where metabolic or post-translational changes (e.g., podocyte injury, proteinuria induction in animal models) are experimentally induced to dissect cellular mechanisms. The referenced PDAC study similarly uses genetic and metabolic perturbation models, illustrating the cross-disciplinary utility of rigorous, mechanism-driven research design. However, whereas puromycin aminonucleoside primarily models glomerular lesion induction, the current study elucidates a cancer-specific RNA modification pathway, underscoring the importance of context and molecular specificity in experimental modeling (internal_article).

Protocol Parameters

• assay | Lactate concentration (cell culture) | 10–20 mM | Used to induce metabolic stress and lactylation in PDAC cells | reference
• assay | NSUN2 knockdown/knockout (CRISPR or siRNA) | Validated loss-of-function | Defines dependence of m5C modification and invasion on NSUN2 | reference
• assay | MeRIP-qPCR (m5C detection) | 1–5 μg total RNA input | Quantifies RNA methylation changes after genetic/metabolic perturbation | reference
• assay | Sciatic nerve invasion (mouse model) | 1×10⁶ PDAC cells per injection | In vivo assessment of tumor–nerve infiltration | reference
• assay | Actinomycin-D chase (mRNA stability) | 5 μg/mL actinomycin D | Measures transcript half-life post-lactylation/NSUN2 modification | reference
• assay | Puromycin aminonucleoside (in nephrology models) | 50–150 mg/kg (rat, i.p.) | Induces podocyte injury and proteinuria in renal research | product_spec
• assay | Puromycin aminonucleoside cytotoxicity (cell culture) | IC₅₀ 48.9 ± 2.8 μM (MDCK-vector) | Assesses nephrotoxic potential in glomerular cell models | product_spec
• assay | Puromycin aminonucleoside solubility in DMSO | ≥14.45 mg/mL | Ensures preparation of concentrated stock solution for cell-based assays | product_spec

Limitations and Transferability

Despite the robust multi-modal approach, several limitations are worth noting. The mechanistic focus on NSUN2 lactylation and its downstream targets, while well-supported in PDAC, may not directly extend to other malignancies or non-neural invasion contexts. The heavy reliance on murine models and established PDAC cell lines, although necessary for in vivo and mechanistic work, may not capture the full spectrum of human tumor heterogeneity (reference). Additionally, while lactylation-driven stabilization of mRNA was clearly demonstrated for CDCP1 and STC1, the broader transcriptomic consequences of NSUN2 lactylation remain to be explored. Transferability to non-cancer or non-epithelial systems—such as renal models using the aminonucleoside moiety of puromycin—should be undertaken with careful validation, as post-translational regulation and RNA methylation may vary between tissues and disease states (workflow_recommendation).

Why this cross-domain matters, maturity, and limitations

Both the referenced PDAC study and internal nephrology articles rely on chemical or genetic perturbations to model disease-relevant cellular stress and post-translational changes. The cross-domain bridge illustrates the broader scientific logic of using defined agents (like puromycin aminonucleoside for podocyte injury, or lactate for metabolic stress) to dissect cellular mechanisms. However, direct mechanistic overlap is limited: while puromycin aminonucleoside is a gold-standard nephrotoxic agent for focal segmental glomerulosclerosis (FSGS) models and proteinuria induction in animal models, it does not directly modulate RNA methylation pathways as described for NSUN2 in PDAC (internal_article). Researchers should adapt protocols and mechanistic hypotheses to the specific molecular context of their system.

Research Support Resources

For investigators developing podocyte injury models or studying nephrotic syndrome, Puromycin aminonucleoside (SKU A3740) is widely used to induce glomerular lesions, proteinuria, and podocyte morphological changes in experimental systems. Its solubility and cytotoxicity profile are well-characterized, supporting reproducible workflows in renal pathology research (product_spec). For RNA modification and metabolic stress studies outside the renal domain, careful protocol adaptation is recommended. For further reading on nephrotoxic injury modeling, see this internal guide.